Human Dihydroorotate Dehydrogenase (hDHODH) catalyzes the stereoselective oxidation of L- dihydroorotate (DHO) to orotate (ORO) in the de novo pyrimidine biosynthesis. Recent studies proved that inhibiting hDHODH constitutes a promising pharmacological strategy for treatment of hematological malignancies, such as acute myeloid leukemia (AML)1,2, and viral pathologies3. During the last few years, MEDSynth research group designed a first generation of inhibitors based on a hydroxypyrazolo[1,5-a]pyridine scaffold, working as unusual carboxylic acid bioisostere, joined to either a biphenyl or a diaryl ether moiety via an amide linker. Within the series, MEDS433 was the most promising compound: hence, it displayed a high in vitro inhibitory activity (IC50 = 1.2 nM), comparable to that of Brequinar (IC50 = 1.8 nM) in the enzymatic assay.4 Despite its high potency, this lead compound suffers from poor solubility and optimization of its drug-like properties is necessary in order to perform further pre-clinical studies. In this work, aiming to improve the solubility without losing in binding affinity for the protein, a new analogues series was developed by bioisosterically replacing the amide linker. Inspired by promising results in literature studies5, several amide non-classical bioisosteres, such as triazoles, oxadiazole and diazo- moieties were embedded in MEDS433 as potential new linkers (Figure 1). Theoretical design, synthesis and enzymatic assay are here presented and discussed.

Design of new human Dihydroorotate Dehydrogenase inhibitors: amide bioisosterism in MEDS433 optimization

Martino, Elena;Villella, Noemi;Vigato, Chiara;Bersani, Matteo;Giorgis Marta;Sainas Stefano.;Boschi, Donatella;Lolli, Marco Lucio
2021

Abstract

Human Dihydroorotate Dehydrogenase (hDHODH) catalyzes the stereoselective oxidation of L- dihydroorotate (DHO) to orotate (ORO) in the de novo pyrimidine biosynthesis. Recent studies proved that inhibiting hDHODH constitutes a promising pharmacological strategy for treatment of hematological malignancies, such as acute myeloid leukemia (AML)1,2, and viral pathologies3. During the last few years, MEDSynth research group designed a first generation of inhibitors based on a hydroxypyrazolo[1,5-a]pyridine scaffold, working as unusual carboxylic acid bioisostere, joined to either a biphenyl or a diaryl ether moiety via an amide linker. Within the series, MEDS433 was the most promising compound: hence, it displayed a high in vitro inhibitory activity (IC50 = 1.2 nM), comparable to that of Brequinar (IC50 = 1.8 nM) in the enzymatic assay.4 Despite its high potency, this lead compound suffers from poor solubility and optimization of its drug-like properties is necessary in order to perform further pre-clinical studies. In this work, aiming to improve the solubility without losing in binding affinity for the protein, a new analogues series was developed by bioisosterically replacing the amide linker. Inspired by promising results in literature studies5, several amide non-classical bioisosteres, such as triazoles, oxadiazole and diazo- moieties were embedded in MEDS433 as potential new linkers (Figure 1). Theoretical design, synthesis and enzymatic assay are here presented and discussed.
13th Young Medicinal Chemist's Symposium - Nuove Prospettive in Chimica Farmaceutica
Virtual Event
26 - 29 Aprile 2021
13th Young Medicinal Chemist's Symposium - Nuove Prospettive in Chimica Farmaceutica
124
124
Martino, Elena; Villella, Noemi;Vigato, Chiara; Cerrina, Matteo; Bersani, Matteo; Giorgis Marta, Sainas, Stefano.; Boschi, Donatella; Lolli, Marco Lucio
File in questo prodotto:
File Dimensione Formato  
book of abstract_final2.pdf

non disponibili

Descrizione: Book of Abstract
Tipo di file: PDF EDITORIALE
Dimensione 10.83 MB
Formato Adobe PDF
10.83 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1852079
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact